To produce a comprehensive overview of macrophages and related cell types in a short review volume is an impossible task. When I selected the topics to be included, some equally important areas were omitted by necessity, and for this I apologize. My choices have been somewhat eclectic, touching subjects of personal interest (such as osteoclast biology and macrophage electrophysiology) or of current fashion (apopto sis, antigen processing, cell adhesion molecules). The book has also had to encompass areas of a more general flavor to provide balance for the general reader (such as reviews of macrophage development, heterogeneity, and function, and of the surface molecules expressed by macrophages). I thank all the authors for their prompt sub missions; all have been of high quality, and my editorial tasks, thankfully, have been minimal. Michael A. Horton London, United Kingdom ix Contents Chapter J An Overview of Receptors of MPS Cells lain Fraser and Siam on Gordon 1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. The Mononuclear Phagocyte System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 3. Diversity of Macrophage Plasma Membrane Receptors. . . . . . . . . . . . . . . . 6 3. 1 A Structural Approach to Classification . . . . . . . . . . . . . . . . . . . . . . . . . . 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3. 2 Multisubunit Receptors 3. 3 Soluble Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3. 4 Lectins and Lectin-Like Receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 4. Functions and Selected Examples. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 4. 1 Growth, Differentiation, and Modulation . . . . . . . . . . . . . . . . . . . . . . . . 14 4. 2 Cell-Cell and Cell-Matrix Interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4. 3 Endocytosis and Scavenger Receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4. 4 Secretory Responses and Biosynthesis of Effector Molecules . . . . . . 17 5. Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 6. References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 . . . . . . . . . . . . . . . . . . . ."

Malnutrition and its related symptoms are both frequent and deleterious effects of cancer treatment. Despite the importance of targeted nutritional interventions in ameliorating these effects, however, publications providing up-to-date information on novel nutritional approaches and strategies are lacking. This book is intended to fill the void by describing and evaluating in detail the nutritional strategies that may be employed to alleviate a wide variety of cancer treatment effects. The guidance provided will help to improve the survival and quality of life of cancer patients, and has the potential to dramatically affect how evidence-based clinical practice is established and improved over the coming decade. The author is a distinguished expert in the field who has more than 25 years of experience in oncology nutrition and has been involved in establishing and implementing a Clinical Nutrition Oncology Program.

This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.

Following an introductory overview, Hyperthermia In Cancer Treatment: A Primer comprehensively describes the biological reasons for associating hyperthermia with radiation and chemotherapy and the biological and clinical effects of hyperthermia on cancerous and normal tissues. The volume 's 20 chapters are arranged in three principal parts: physical and methodological studies, biologic principles, and clinical studies.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of particular malignancy? The few general oncology text books are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals fre quently publish good in-depth reviews of cancer topics, and published sym posium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by divid ing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Volume 11 in this series discusses therapeutic applications of stem cells in disease and tissue injury. Coverage includes pluripotent stem cells, which can give rise to the endodermal, ectodermal, and mesodermal lineages; multipotent stem cells, which can generate all cells in a particular lineage and unipotent stem cells, which can give rise to only one cell type. This volume also examines cancer stem cells, tumor-initiating cells which possesses the capacity of self-renewal and can give rise to the heterogeneous lineages of cancer cells that comprise the tumor. Coverage extends to molecular mechanisms underlying the derivation and expansion of human embryonic stem cells, the role of specific proteins in the maintenance and inhibition of extraembryonic differentiation of these cells and the role of signaling responsible for the self-renewal of mouse embryonic stem cells. Nine chapters discuss the clinical importance of cancer stem cells, encompassing glioma, leukemia, ovarian cancer, pediatric sarcomas and head and neck squamous cell carcinoma. The role of cancer stem cells is also elucidated in epithelial-to-mesenchymal transition in spreading head and neck squamous cell carcinoma. The book goes on to survey therapeutic application of stem cells of hematopoietic and non-hematopoietic origin for regeneration of bones, including in osteoporotic bone disease; to illuminate the application of hematopoietic stem cells in bone regeneration and to discuss their use as a biomarker to facilitate determination of a treatment. The contributors review cells as biomarkers for pediatric solid tumors, and weigh the advantages and limitations of hematopoietic stem cell transplantation. Also included are details of neural stem cell engraftment in the injured spinal cord; the regenerative potential of neural stem/progenitor cells of newborns and cancer gene therapy potential using neural stem cells. Like the preceding volumes in the series, this book is distinguished for its comprehensive approach, its distinguished roster of 58 contributors representing 10 different countries and its thorough review of leading-edge technology and methods.

The emotional pressures on cancer patients and their families are increasing and traditional supports are decreasing. This book attempts to provide a readable, authoritative and balanced review of the emotional pressures and coping methods of cancer patients, and the help currently available to them. The special problems of children and terminal patients with cancer, and the role of the family in coping, are also examined. A balanced and critical assessment is made of defects in health organisation, training of personnel and attitudes to cancer patients in Western society. A similar assessment is made of the growing tendency to self help, mutual help and group activities for such patients. While each individual needs to select coping aids best suited to his or her own temperament, medical advisors need to make more time available for discussion of technical, emotional, social and sexual problems. The availability of a cancer-treating "team" makes this feasible. Chapters were invited from physicians, psychiatrists, psychologists and sociologists expert in this field, and they have responsed to the challenge of writing in non-technical language. This is so that readership can cross disciplinary boundaries and thus stimulate physicians, nurses, psychologists, sociologists, clergy and others, to satisfy some of the currently unmet needs of cancer patients. The reader may note a small amount of overlap between some chapters, permitted in order to maintain continuity and make each chapter complete in itself.

Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.

Hepatocellular Carcinoma: Targeted Therapy provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options. This volume also provides an up-to-date guide for treatment that explores not only traditional treatments, but newer investigational treatment options including, surgical resection, liver transplantation, ablation (radiofrequency, microwave), percutaneous ethanol or acetic acid injection, transarterial chemoembolization (TACE), intra-arterial radiation therapy, and systemic chemotherapy. Heptocellular Carcinoma: Targeted Therapy will be of great value to all health care professionals and trainees worldwide who have an interest in the diagnosis and treatment of HCC, including surgeons, medical oncologists, radiologists, radiation oncologists, and pathologists.

The first edition of Oncogenes (1989) focused on several of the better known transforming mechanisms and surveyed a spectrum of solid tumors and hematologic malignancies. Several of the nearly 50 known oncogenes most relevant to human disease were examined. In contrast, this volume presents a very different profile and balance of subject material that reflects the rapidly changing field of molecular oncology and its newly emerging concepts. Among the most important discoveries of the past 4 years are the identification of nearly a dozen different tumor suppressor genes and the finding of an entirely new class of cancer-causing gene (bcl-2) that acts by inhibiting cell death rather than stimulating cell proliferation. This edition begins by reviewing selected malignancies in which our earlier search for clinically relevant oncogenes has led to more focused studies on gain-of-function and loss-of-function genetic abnormalities, as well as autocrine and paracrine growth factor loops known to regulate tumor physiology and malignant cell behavior. Curiously, many of these genetic and functional abnormalities are shared by several different tumor types and are not uniformly present in all tumors of the same type. This observation brings up molecular questions about the tissue-specific determinants that underlie individual cancers and also gives added impetus to the suggestion that molecular abnormalities (referred to as tumor markers) be included among the histopathologic features used for clinical diagnosis and manage ment."

The Hippo signaling pathway is rapidly gaining recognition as an important player in organ size control and tumorigenesis, and many leading scientists are showing increased interest in this growing field and it's relation to cancer. The chapters in this volume cover virtually all aspects of tumor biology, because members of the Hippo Pathway have been associated with numerous well-established cell signaling pathways, just to name a few; Ras, Wnt, TGFbeta and p53. Moreover, Hippo signaling is not solely involved in regulating "classic" tumor characteristics such as cell proliferation, survival and growth, but is also diversely involved in cell-autonomous and non-cell-autonomous differentiation, migration and organ size control. The primary audience are researchers interested in basic science in the areas of tumor suppression, cell cycle and size regulation, development and differentiation.

Psycho-oncology integrates research and clinical wisdom across multiple disciplines -- including oncology, psychiatry, psychology, surgery, radiotherapy and palliative care, among others -- in the service of educating oncologists, physicians, psychiatrists and other mental health care providers, and hospital chaplains about the psychological and psychosocial challenges faced by patients with neoplastic disorders. As cancer treatment has improved, the number of patients deemed "cancer survivors" has grown, along with their more complex, long-term mental health issues. This book assists care providers in meeting the challenge presented by this population. Written by international experts in psycho-oncology, the volume offers a compact overview of the clinical elements in this field, with a primary focus on the biopsychosocial aspects of individuals with cancer as well as their families and important people in their lives. Its "bench-to-bedside" approach ensures that the techniques presented are evidence-based, practical, and effective. The following are among the book's many helpful features:

- The chapters are designed to stand alone, to be shared or consulted as needed, but they also develop a coherent and sequential discussion about management of the patient with cancer, as well as concerns involving the patient's family. Thus, the book as a whole serves as a comprehensive textbook in the field.- The book's structure is based on psychosocial staging, much as the disease itself is staged, and progresses from discovery to initial diagnosis, treatment intervention, remission, and so forth. Each phase has its own challenges -- for patient, family, and care provider -- and supportive strategies are offered.- Because identifying those patients in need of support and treatment intervention is critical, the authors provide screening techniques, as well as an entire chapter devoted to quality of life assessment, to help clinicians recognize struggling patients and alleviate their distress. - A final chapter addresses developing trends in psycho-oncology and suggests that international standards of care for the cancer patient must include competent and compassionate psychosocial assessment and treatment.

Concise and clinically focused, yet addressing the broad issues as well, Psycho-oncology offers cutting-edge information and invaluable assistance to physicians and mental health professionals responsible for managing patients, and the families of patients, with neoplastic disorders.

Andrew Arnold The past several years have been a time of intense excitement and have brought major advances in the understanding and treatment of endocrine neoplasms. This is therefore an excellent point at which to undertake a broad based overview of the state of the art in endocrine neoplasia for the Cancer Treatment and Research series. Because of the wide and interdisciplinary readership of this series, our aim for each chapter has been to provide ample background for those not highly familiar with the topic, while emphasizing the most recent advances. Furthermore, the chapters have been written with the clinician in mind, whether she or he is an oncologist, endocrinologist, surgeon, generalist, pathologist, or radiologist. As such, the authors' mission has been to focus on clinically relevant issues and to present the scientific basis of current or potential future advances in a manner easily digestible to the nonexpert. Endocrine tumors often cause problems for the patient by virtue of their hormonal activity, which may frequently (but certainly not always) over shadow the adverse consequences related to their mass per se. In fact, it is important to keep in mind that endocrine tumors can manifest two biologically separable but often intertwined properties, namely, increased cell mass and abnormal hormonal function. These need not go hand in hand, and their distinction has definite clinical relevance in, for example, the increasingly recognized problem of incidentally discovered adrenal or pituitary masses."

Cell growth, one of the most fundamental of biological processes, has long been among the least understood. On April 24-28, 1984 sci- entists convened from around the world in Canada's Banff National Park for The International Cell Cycle Society's 10th Conference. Their purpose was to evaluate recent developments in the field of cell prolif- eration and to explore the interrelationship between cell growth, de- velopment, and differentiation, and proliferative diseases such as can- cer. Growth, Cancer, and the Cell Cycle collects those conference papers that present the most recent advances in this field. The first section of the book is Gene Expression and Development During Growth. It examines the structure and function of chromatin, DNA unwinding proteins, and nonhistone nuclear proteins, then ex- plores transcriptional, translational, and post-translational regulation during the cell cycle and the interrelationship and coordinate regula- tion of cell growth, differentiation, and gene expression. The second section, Growth Activation and Dormancy, focuses upon the events that occur during the transition between active cell growth and proliferative quiescence. The role of DNA strand breaks, protein kinase activity, growth regulatory factors, and the cytoskeleton are examined. Section three discusses The Topology of the Cell Cycle. It reviews genetic approaches for determining the sequence of events and cau- sality relationships that comprise and coordinate the many separate processes involved in cell cycle progression and describes the use of multipara meter flow cytometry to characterize the mammalian cell cy- cle and intracellular metabolic and transitional growth states.

Exciting new developments and discoveries of the last two decades are beginning to shed light on the complex biology of brain tumors and are advancing our understa- ing of the cellular and molecular processes involved in their initiation, progression, and clinical and biological behavior. The disease process in brain tumors is quite complex and the resulting tumors are characterized by a high degree of biological and clinical diversity. Thus, despite the advances of the last two decades, prognosis for patients with malignant brain tumors remains abysmal. Significant progress in the diagnosis, treatment and, ultimately, prevention of these tumors will require both the timely h- nessing of the advances in basic and clinical brain tumor research, and a continuing concerted effort at increasing our understanding of brain tumor biology, in particular, the molecular genetic changes and perturbations of cellular pathways involved in brain oncogenesis and which drive the biological and clinical behavior of the tumors. Brain tumor diagnosis and prognosis, which is still largely based on histopathology and other clinical criteria, will, in the future, acquire a significant molecular component, with the incorporation of knowledge of genes that are mutated, over-expressed, deleted, silenced, or functionally altered in the tumors. Treatment strategies for brain tumors, rather than being empirical, will be rationally developed based on an understanding of the cellular and molecular mechanisms and targets that have been activated, suppressed, or otherwise altered.

In the United States alone, the incidence of new cases of thoracic neoplasms is over 180,000. Each year, over 170,000 individuals are expected to die of their cancer. Lung cancer is the most common of the thoracic neoplasms. It is the leading cause of cancer death in both men and women, accounting for 28% of all cancer deaths in the United States. Thoracic Oncology provides an up-to-date and concise review of the various thoracic neoplasms and offers a better understanding of the biology, natural history, diagnosis and treatment of these malignancies. This book will be of particular interest to clinicians interested in thoracic neoplasms, to better understand and treat them.

In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance.

This series of books, devoted to aspects of blood cell biochemistry, development, immu nology, and ultrastructure, has evolved and separated from the long-established Plenum series Subcellular Biochemistry. It is the intention of these volumes to draw together related areas of investigation and to provide, in the fullness of time, complete coverage of this rapidly advancing important biomedical discipline. Both fundamental and medically applied topics, dealing with normal and pathological cells, will be included. This, the first volume of the series, contains a diverse collection of chapters, all of which relate to erythroid cells. The range of material included is extremely broad and the authors have used contrasting technical approaches, both within their personal experimen tal studies and within their manuscripts. This has led to the production of a very interest ing compilation, which does, nevertheless, possess a strong overall thematic unity. As with all edited volumes, some topics of importance and interest are not included. This may be because of oversight on my part, as editor, or because the authors originally selected failed to submit their manuscript by the agreed-upon submission date. For these omissions I take full responsibility and trust that at least some of the topics omitted, for instance membrane cation transport systems, will be covered within a future volume of the series. This book commences with two chapters of a developmental nature."

Focused on the discovery of precise molecular targets for the development of the cancer preventive agents, "Cancer Prevention: Dietary Factors and Pharmacology" provides researchers and non-researchers with practical methodologies for developing and validating small molecule and phytochemical-derived drug discovery and mechanisms by which these compounds can modulate distinct target proteins involved in oncogenic signaling. While this volume is primarily focused toward cancer prevention research, the range of techniques demonstrated in the book also provides an introduction of cancer prevention research methods to researchers outside the field. Chapters deal with a critical discussion of both laboratory and clinical topics, with each chapter containing both a discursive section along with a detailed methods section. As part of the "Methods in Pharmacology and Toxicology" series, this meticulous volume includes the kind of key implementation advice that seeks to ensure successful results in the lab.

Practical and authoritative, "Cancer Prevention: Dietary Factors and Pharmacology" aims to guide research toward identifying molecular targets and conducting human studies with phytochemicals which would, ideally, provide an enhanced approach to the goal of personalized cancer prevention.

Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

Rectal cancer is one of the most prevalent cancers world-wide. It is also a paradigm for multimodal management, as the combination of surgery, chemotherapy and radiotherapy is often necessary to achieve the optimal outcome. Recently, international experts met in Heidelberg, Germany to discuss the latest developments in the management of rectal cancer, including the anatomic and pathologic basis, staging tools, surgical concepts including fast-track surgery and laparoscopic resection, functional outcome after surgery and the role of radio- and chemotherapy. This monograph summarizes this meeting and gives an extensive overview of the current concepts in management of rectal cancer.